Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the ESMO Annual Congress 2016
July 19 2016 - 6:35AM
Business Wire
Data from the Phase 1 portion of the ECHO-202
study evaluating epacadostat in combination with Keytruda®
(pembrolizumab) to be highlighted as a poster discussion
Incyte Corporation (Nasdaq:INCY) announces that updated data
from the Phase 1 portion of the ECHO-202/KEYNOTE-037 trial has been
accepted for a poster discussion at the European Society for
Medical Oncology (ESMO) Annual Congress 2016, taking place in
Copenhagen, Denmark from October 7-11, 2016. The ECHO-202 study
(NCT02178722) is evaluating the safety and efficacy of epacadostat,
Incyte’s selective IDO1 inhibitor, in combination with Keytruda®
(pembrolizumab)*, Merck’s anti-PD-1 therapy.
Poster details:
Epacadostat Plus Pembrolizumab in Patients With Advanced
Melanoma and Select Solid Tumors: Updated Phase 1 Results From
ECHO-202/KEYNOTE-037 (Abstract #1110PD)
- Monday, 10 October 2016 from
11:00-12:00 CET
Full session details and data presentation listings for ESMO
2016 can be found at
http://esmo.org/Conferences/ESMO-2016-Congress/Programme.
About Epacadostat (INCB024360)
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunosuppressive
enzyme that modulates the anti-tumor immune response by promoting
regulatory T cell generation and blocking effector T cell
activation, thereby facilitating tumor growth by allowing cancer
cells to avoid immune surveillance. Epacadostat is a
first-in-class, highly potent and selective oral inhibitor of the
IDO1 enzyme that reverses tumor-associated immune suppression and
restores effective anti-tumor immune responses. In single-arm
studies, the combination of epacadostat and immune checkpoint
inhibitors has shown proof-of-concept in patients with unresectable
or metastatic melanoma. In these studies, epacadostat combined with
the CTLA-4 inhibitor ipilimumab or the PD-1 inhibitor pembrolizumab
improved response rates compared with studies of the immune
checkpoint inhibitors alone. A Phase 3 study, ECHO-301, evaluating
the combination of epacadostat with the anti-PD-1 antibody
pembrolizumab for the first-line treatment of patients with
advanced or metastatic melanoma has recently been initiated.
Ongoing Phase 1 and Phase 2 studies are investigating epacadostat
in combination with PD-1 and PD-L1 inhibitors in a variety of other
cancer histologies.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based
biopharmaceutical company focused on the discovery, development and
commercialization of proprietary therapeutics. For additional
information on Incyte, please visit the Company’s website at
www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the presentation of data regarding the Company’s ECHO-202
study, contain predictions, estimates and other forward-looking
statements. These forward-looking statements are based on the
Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially,
including unanticipated developments and the risks related to the
efficacy or safety of the Company’s development pipeline, the
results of further research and development, the high degree of
risk and uncertainty associated with drug development, clinical
trials and regulatory approval processes, other market or economic
factors and competitive and technological advances; and other risks
detailed from time to time in the Company’s reports filed with the
Securities and Exchange Commission, including its Form 10-Q for the
quarter ended March 31, 2016. Incyte disclaims any intent or
obligation to update these forward-looking statements.
* KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160719005754/en/
Incyte CorporationMedia:Catalina Loveman, +1
302-498-6171cloveman@incyte.comorInvestors:Michael Booth,
DPhil, +1 302-498-5914mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2024 to May 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From May 2023 to May 2024